Patents Examined by Benjamin J Packard
  • Patent number: 11903934
    Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: February 20, 2024
    Assignee: BIOVERSYS AG
    Inventors: Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
  • Patent number: 11890378
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: February 6, 2024
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Patent number: 11883510
    Abstract: The present invention relates to a dental composition comprising a photoinitiator system comprising a particulate carrier supporting a coinitiator covalently bonded to the surface of the carrier. Furthermore, the present invention relates to a use of the particulate carrier in a dental composition. The particulate carrier displays multiple covalently bonded tertiary amino groups and/or tertiary phosphine groups on the surface, for crosslinking monomers, oligomers and/or polymers having one or more polymerizable double bonds.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: January 30, 2024
    Assignee: DENTSPLY SIRONA INC.
    Inventors: Maximilian Maier, Joachim E. Klee, Christian Scheufler, Caroline Renn, Florian Szillat
  • Patent number: 11873308
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: January 16, 2024
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Patent number: 11872255
    Abstract: Provided herein are methods and compositions related to bacteria of genus Rothia useful as therapeutic agents for dental caries.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: January 16, 2024
    Assignee: Forsyth Dental Infirmary for Children
    Inventors: Pooja Balani, Felicitas Bidlack, Xuesong He, Megan Pugach-Gordon, Wenyuan Shi, Jacqueline Starr, Daniel Ferrer
  • Patent number: 11872205
    Abstract: Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).
    Type: Grant
    Filed: January 26, 2023
    Date of Patent: January 16, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Gerald F. Swiss, Jesse Crowne, Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11865217
    Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: January 9, 2024
    Assignees: BioPhysics Pharma, Inc.
    Inventors: John J. Masiz, Zhen Zhu
  • Patent number: 11857565
    Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: January 2, 2024
    Assignee: SEAGEN INC.
    Inventors: Svetlana O. Doronina, Philip Moquist
  • Patent number: 11857651
    Abstract: A dental composition comprising doped T1O2 nanoparticles, and a curable resin material, wherein the curable resin material comprises a polymer precursor component, and wherein the dopant may be one or more of, for example, N (nitrogen), Ag (silver), F (fluorine), P (phosphorus), and P04 (phosphate). A method of using the dental composition in a dental application. The dental composition may be antibacterial in the absence of visible light or UV light.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: January 2, 2024
    Assignees: The Board of Regents of the University of Oklahoma, UT-Battelle, LLC
    Inventors: Fernando Luis Esteban Florez, Sharukh Soli Khajotia, Adam Justin Rondinone
  • Patent number: 11857675
    Abstract: Methods comprising the insertion of a uterine cervical device into the lower part of the uterine cavity and endocervix for decreasing the incidence of the human papillomavirus in women, mainly types 16 and 18, thus preventing the development of uterine cervical cancer; for modifying the cervical microbiota; for increasing leukocytes and protecting against sexually transmitted infections in women.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: January 2, 2024
    Inventors: Eleonora Sanders Esparza, Barbara Sanders Esparza
  • Patent number: 11850303
    Abstract: A gel and suppository and method to provide the gel and the suppository, are disclosed herein. The gel comprising: between 50 and 150 millimolar of lactic acid concentrate; and between 0.5 and 10 millimolar of hydrogen peroxide concentrate. The suppository comprising: between 22.5 and 67.5 milligrams of lactic acid concentrate; and between 1 and 20 milligrams of hydrogen peroxide concentrate.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: December 26, 2023
    Assignee: Uqora, Inc.
    Inventor: Spencer Gordon
  • Patent number: 11849731
    Abstract: Provided is a method of imparting antibacterial and deodorant functions by reacting iodic acid, and a material that is given antibacterial and deodorant functions. The method of imparting antibacterial and deodorant function is as follows. Reacting iodate to a material that includes elements capable of producing iodate insoluble in water and non-toxic to a living body to form iodic acid of such elements on the surface of the material, thereby the iodate is made to be supported so that antibacterial and deodorant is possible without elution of said iodate to the outside.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: December 26, 2023
    Assignee: Kaken Co., Ltd.
    Inventors: Katsuyoshi Tatenuma, Yoshiaki Kinase, Yuri Natori, Junko Matsui
  • Patent number: 11850324
    Abstract: The present invention relates to bioinks based on undenatured collagen, kits containing the same, and methods of printing three-dimensional structures using the bioinks.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 26, 2023
    Assignee: Advanced Biomatrix, Inc.
    Inventors: David Bagley, Bowman Bagley, Dale Peterson
  • Patent number: 11844802
    Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: December 19, 2023
    Assignees: Emory University, The US Govt as represented by the Dept of VA
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Patent number: 11844795
    Abstract: Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: December 19, 2023
    Inventors: Sarah F. Blanchette, Daryl C. Drummond, Jonathan Basil Fitzgerald, Victor Moyo
  • Patent number: 11840499
    Abstract: A biobased fatty acid arginate may be synthesized according to the disclosed process by combining arginine and a fatty acid. The fatty acid arginate may have certain beneficial properties, such as surfactant properties or acting as an antimicrobial agent.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: December 12, 2023
    Assignee: The United States of America, as represented by The Secretary of Agriculture
    Inventors: Helen N Lew, Xuetong Fan, Kun Huang, Jianwei Zhang
  • Patent number: 11833139
    Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: December 5, 2023
    Assignee: BIOVERSYS AG
    Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
  • Patent number: 11826383
    Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: November 28, 2023
    Assignee: EXELA PHARMA SCIENCES, LLC
    Inventors: John Maloney, Aruna Koganti, Phanesh Koneru
  • Patent number: 11814402
    Abstract: This invention relates to a series of binuclear palladacycle compounds, and methods for the production of these compounds, that are suitable for use in the treatment of cancer. In particular embodiments, R1 is phenyl substituted with two occurrences of isopropyl, R2 is Cl, and R3 is independently one or more substituents selected from —O(CH2)2O(CH2)2OH, —O(CH2)2O(CH2)2O(CH2)2OH, —O(CH2)2OH, and —O(CH2)2O(CH2)2OCH3.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 14, 2023
    Assignees: Stellenbosch University, University of Cape Town
    Inventors: Angelique Blanckenberg, Annick Van Niekerk, Selwyn Frank Mapolie, Sharon Prince
  • Patent number: 11808775
    Abstract: A method of detecting the presence of a cathinone moiety in a sample, such as a suspected illicit drug sample, which comprises contacting the sample with a solution comprising neocuproine, a source of copper(II) and a catalyst and observing a colour change, where present, that correlates with the presence of cathinone. The method is operable at environmental temperature. Mechanical elements may be employed to accelerate the colour change if desired.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 7, 2023
    Inventors: Shanlin Fu, Morgan Philp, Ronald Shimmon